Loading...
XTAI
4119
Market cap274mUSD
Jun 13, Last price  
67.70TWD
1D
-0.44%
1Q
-18.34%
Jan 2017
19.63%
IPO
294.52%
Name

SCI Pharmtech Inc

Chart & Performance

D1W1MN
P/E
15.13
P/S
5.31
EPS
4.47
Div Yield, %
1.85%
Shrs. gr., 5y
1.73%
Rev. gr., 5y
-8.34%
Revenues
1.52b
+26.54%
905,738,000994,676,0001,037,853,0001,262,572,0001,292,734,0001,491,862,0001,810,501,0001,903,100,0001,301,050,0001,939,913,0002,355,747,0002,689,222,000864,217,000899,738,0001,204,159,0001,523,738,000
Net income
535m
+81.42%
166,312,000171,244,00090,016,000194,449,000159,938,000264,839,000373,902,000416,955,000190,976,000447,237,000571,101,000360,124,00055,696,000308,780,000294,721,000534,678,000
CFO
861m
+298.82%
316,958,000218,959,000249,546,000385,571,000238,571,000358,771,000663,239,000502,106,000281,651,000480,183,000791,596,000971,528,000280,278,000296,565,000215,767,000860,516,000
Dividend
Jul 01, 20241.25 TWD/sh
Earnings
Aug 07, 2025

Profile

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexmethylphenidate HCl. The company's intermediate products comprise Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Diethyl dipropylmalonate, Diethyl ethyl(1-methylbutyl)malonate, Pyrogallolaldehyde, Benzhydrylamine, 1-Benzhydrylazetidin-3-ol, 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one, N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic acid HCl, (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol HCl, and (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol. Its intermediate products also consists of (S)-3-(methylmino)-1-(2-thi-enyl)propan-1-ol, (R)-3-(Methylamino)-1-phenylpropanol, (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol, Menthadienol, 5-pentylbenzene-1,3-diol Olivetol, Methyl 2,4-dihydroxy-6-pentylbenzoate, and Ethyl 2,4-dihydroxy-6-pentylbenzoate Ethyl Olivetolate. The company also provides custom manufacturing services. It sells its products in Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, Netherlands, and internationally. The company was incorporated in 1987 and is based in Taoyuan City, Taiwan.
IPO date
Aug 12, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,523,738
26.54%
1,204,159
33.83%
899,738
4.11%
Cost of revenue
1,325,453
1,043,859
780,768
Unusual Expense (Income)
NOPBT
198,285
160,300
118,970
NOPBT Margin
13.01%
13.31%
13.22%
Operating Taxes
112,179
69,469
79,040
Tax Rate
56.57%
43.34%
66.44%
NOPAT
86,106
90,831
39,930
Net income
534,678
81.42%
294,721
-4.55%
308,780
454.40%
Dividends
(149,387)
(23,846)
Dividend yield
1.38%
0.22%
Proceeds from repurchase of equity
957,600
BB yield
-9.03%
Debt
Debt current
406,004
196,946
112,828
Long-term debt
593,222
850,332
433,574
Deferred revenue
7,448
6,837
4,108
Other long-term liabilities
13,187
22,536
20,530
Net debt
179,320
(225,399)
171,534
Cash flow
Cash from operating activities
860,516
215,767
296,565
CAPEX
(946,638)
(1,029,360)
(1,167,584)
Cash from investing activities
(1,009,351)
(866,203)
(1,009,087)
Cash from financing activities
(210,840)
1,425,665
547,119
FCF
(689,091)
(1,067,018)
(1,174,634)
Balance
Cash
692,756
1,031,055
264,373
Long term investments
127,150
241,622
110,495
Excess cash
743,719
1,212,469
329,881
Stockholders' equity
2,727,852
2,866,363
2,350,189
Invested Capital
5,744,235
4,959,331
3,865,498
ROIC
1.61%
2.06%
1.18%
ROCE
3.01%
2.54%
2.77%
EV
Common stock shares outstanding
119,857
109,609
109,327
Price
90.60
-6.40%
96.80
11.69%
86.67
16.07%
Market cap
10,859,065
2.35%
10,610,151
11.98%
9,475,347
16.20%
EV
11,038,385
10,384,752
9,646,881
EBITDA
432,077
305,594
209,582
EV/EBITDA
25.55
33.98
46.03
Interest
5,540
6,290
1,072
Interest/NOPBT
2.79%
3.92%
0.90%